Obstructive sleep apnea is far more common among your patients than most charts reflect. Among U.S. adults aged 30 to 70, the U.S. Preventive Services Task Force estimates mild OSA with daytime sleepiness in 14% of men and 5% of women, and moderate-to-severe OSA in 13% of men and 6% of women. Diagnosis rates climbed 442% between 1999 and 2010, driven largely by rising obesity — yet a substantial share of affected patients remain undiagnosed, especially in primary care, cardiology, and ENT practices, where OSA often hides behind more visible complaints: resistant hypertension, atrial fibrillation, treatment-resistant type 2 diabetes, or unexplained daytime fatigue. Risk climbs further with higher BMI, craniofacial anatomy, and age, and prevalence runs higher among Black, Hispanic/Latino, and Native American/Alaska Native patients — worth factoring into who gets screened/tested.

For physicians already managing those comorbidities, the harder problem usually isn’t suspecting OSA — it’s what happens after diagnosis. Many patients prescribed CPAP struggle to stick with it long-term: mask discomfort, claustrophobia, travel, all take a toll. When a patient quietly stops using the machine, the cardiovascular and metabolic risks you were trying to manage keep accruing, untreated and often unreported at the next visit.

“We recommend that sleep physicians consider prescription of oral appliances, rather than no treatment, for adult patients with obstructive sleep apnea who are intolerant of CPAP therapy or prefer alternate therapy.” — AASM/AADSM Joint Clinical Practice Guideline

This is where oral appliance therapy (OAT) fits into the treatment pathway. The joint clinical practice guideline from the American Academy of Sleep Medicine and the American Academy of Dental Sleep Medicine is direct on this point. CPAP remains superior at reducing sleep-disordered breathing when it’s actually used — but the guideline also notes that “patient adherence to [oral appliance] treatment may be higher than for CPAP therapy.”

A therapy your patient will actually wear every night beats a therapy sitting in a closet.

That adherence gap isn’t abstract in our experience — it’s the whole reason a dedicated OAT referral pathway matters. Across the patients we treat at Sleep Houston, roughly 98% wear their custom oral appliance the full recommended dose: eight hours a night, seven nights a week, verified at follow-up visits and confirmed with repeat sleep testing rather than taken on the patient’s word.

Compare that to CPAP, where real-world compliance is commonly reported at only around 25–30% of patients meeting even the standard four-hour, most-nights threshold, and average nightly use among those who do stick with it often lands closer to five hours — short of a full night’s protection. None of this means CPAP is a worse therapy on paper; used correctly and consistently, it remains the gold standard for reducing AHI. It means the therapy your patient will actually use, night after night, is frequently the one that ends up protecting them.

The landmark SAVE trial illustrates exactly this distinction. Enrolling patients with moderate-to-severe OSA and established cardiovascular disease, it showed CPAP was clearly effective when actually worn — AHI dropped from a baseline of about 29 events per hour to 3.7 events per hour on treatment. But real-world use told a different story: average CPAP adherence over the 3.7-year follow-up was only 3.3 hours a night, and just 42% of patients averaged four or more hours nightly. The trial did not demonstrate a reduction in major cardiovascular events (McEvoy et al., New England Journal of Medicine, 2016). That doesn’t mean CPAP is ineffective — it means efficacy while worn and effectiveness in the real world are different questions, and closing that gap is precisely what a therapy patients will actually use, night after night, can do.

At Sleep Houston, our practice is built around the collaborative physician-dentist model the guideline calls for. We are not a substitute for your sleep medicine referral or diagnostic workup — we’re the treatment arm for the patients on your panel who need OAT specifically: those who’ve failed CPAP, refuse it outright, or present with mild-to-moderate OSA where a custom, titratable appliance is an appropriate first-line option. The guideline isn’t limited to mild disease, either — CPAP-intolerant patients with moderate-to-severe OSA are appropriate candidates too, provided efficacy is confirmed objectively rather than assumed.

Referring is straightforward. If a patient hasn’t been tested, we can facilitate a home sleep apnea test using validated platforms including WatchPAT and SANSA testing equipment— an accessible, low-friction diagnostic step for patients unlikely to complete an in-lab polysomnogram. Results and a clear, physician-ready summary come back to you directly.

If OSA is confirmed and CPAP isn’t the right fit, we fabricate a custom, titratable oral appliance — we use SomnoMed and ProSomnus devices exclusively, never over-the-counter or non-adjustable options — and confirm efficacy with follow-up sleep testing, exactly as the guideline recommends, rather than assuming symptom relief equals resolved apnea.

One complaint we hear consistently from referring physicians: a patient goes out to a specialist, and then silence. No word on whether the study was completed, what it showed, or whether treatment ever started — until the patient turns up at a follow-up visit no better than before. We built our process specifically to close that loop. Every referral generates written correspondence back to you at each stage: a summary when testing is completed, a treatment plan once oral appliance therapy begins, and objective outcome data — AHI changes, oxygen nadir findings, and positional or REM-related patterns — once efficacy is confirmed with follow-up sleep testing. You find out what happened with your patient from us, not by asking them at their next appointment.

If you have patients with resistant hypertension, atrial fibrillation, treatment-resistant type 2 diabetes, or a bed partner who insists the snoring has to stop — and CPAP hasn’t worked, or you suspect it won’t — we welcome the referral. We’re glad to discuss candidacy on a specific case before you refer. Reach Sleep Houston at 713-828-8587 or SleepHouston.com.

Dr. Hans Schleicher, DDS, D-ABSDM, has practiced dentistry for approximately 25 years with an exclusive focus on dental sleep medicine and TMJ disorders. He is the founder and sole treating provider of Sleep Houston PLLC, located at 9099 Katy Freeway, Suite 100, Houston, TX 77024.